Literature DB >> 11334026

TNF is here to stay--revisited.

T L ten Hagen, A M Eggermont, F J Lejeune.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11334026     DOI： 10.1016/s1471-4906(00)01850-0

Source DB:  PubMed          Journal:  Trends Immunol        ISSN： 1471-4906            Impact factor:   16.687


× No keyword cloud information.
  3 in total

Review 1.  Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy.

Authors:  Alexander M M Eggermont; Timo L M ten Hagen
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

2.  Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion.

Authors:  B van Etten; M R de Vries; M G A van IJken; T E Lans; G Guetens; G Ambagtsheer; S T van Tiel; G de Boeck; E A de Bruijn; A M M Eggermont; T L M ten Hagen
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

Review 3.  Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.

Authors:  Cornelis Verhoef; Johannes H W de Wilt; Dirk J Grünhagen; Albertus N van Geel; Timo L M ten Hagen; Alexander M M Eggermont
Journal:  Curr Treat Options Oncol       Date:  2007-12-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.